- Home
- CHI vs NEO Comparison
CHI vs NEO Comparison
Compare CHI & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | NEO |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2002 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CHI | NEO |
|---|---|---|
| Price | $12.51 | $15.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 167.0K | ★ 3.0M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $5.09 |
| 52 Week High | $13.50 | $16.17 |
Technical Indicators
Market Signals| Indicator | CHI | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 65.38 |
| Support Level | $10.94 | $11.49 |
| Resistance Level | $12.80 | N/A |
| Average True Range (ATR) | 0.26 | 0.76 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 38.60 | 84.13 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.